HOME >> MEDICINE >> NEWS
Failed lung cancer drug could help shrink breast tumors

Giving women with early breast cancer a drug called gefitinib (Iressa) before surgery could reduce the size of their tumours, suggests a randomised trial published online today (Tuesday May 17, 2005) by THE LANCET ONCOLOGY. Gefitinib has been tested in clinical trials as a treatment for lung cancer but did not help patients live longer overall. Large-scale studies to assess its use in breast cancer, as a treatment prior to surgery, are now being designed, state the authors.

Some breast cancers are hormone sensitive and proliferate in the presence of oestrogen. But in trials where women with this type of breast cancer were given pre-surgical treatment to block hormones only half were found to respond. For this reason many doctors use chemotherapy prior to surgery, which can have negative side effects and cause substantial mortality.

A receptor called EGFR (epidermal growth factor receptor) is present on some hormone sensitive breast cancers and is associated with poor prognosis and failure to respond to hormone-blocking therapy. Charles Coombes (Imperial College and Hammersmith Hospital, London, UK) and colleagues tested whether inhibiting this receptor with a drug called gefitinib might suppress breast cancer cell proliferation. They recruited 56 postmenopausal women with breast cancer that was hormone sensitive and positive for EGFR from hospitals in London. 27 women were assigned gefitinib and an aromatase inhibitor called anastrozole (Arimidex) and 29 were assigned gefitinib and placebo for 4-6 weeks prior to receiving surgery. Tumours were reduced in size by 30-99% in 12 of 22 assigned gefitinib and anastrozole and in 14 of 28 patients assigned gefitinib and placebo.

Professor Coombes comments: "Gefitinib, combined with an aromatase inhibitor, might have a role in the neoadjuvant treatment of breast cancer by reducing the size of the tumour more rapidly. Studies are now being designed to assess this approach."


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
1-212-633-3810
Lancet
16-May-2005


Page: 1

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. Stomach cancer rate set to fall further 25 percent over next decade
4. MRI finds breast cancer before it becomes dangerous
5. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
6. New cause of tamoxifen resistance in breast cancer cells discovered at Lombardi
7. Pathway links inflammation, angiogenesis and breast cancer
8. Using MRI for diagnosis could help prevent breast cancer progression
9. Electric fields have potential as a cancer treatment
10. Shining light on pancreatic cancer
11. Method shows promise for early detection of pancreatic cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/13/2018)... ... September 13, 2018 , ... Pulsara is honored to be represented ... Cycle Conference on September 19-22 in Chicago. Dr. Woodson, ER Physician and Founder/CEO ... a talk titled, “Your Clinical Communication & Collaboration (CC&C) is Not Enough: Why You ...
(Date:9/12/2018)... ... ... Today, Sterling , a rope and life-safety equipment company, announced two ... of the Lotus Flower Tower in Canada’s Cirque of the Unclimbables. Although Jim was ... duo decided to persevere and with some assistance from rigger Pat Goodman and cinematographer ...
(Date:9/12/2018)... Ohio (PRWEB) , ... September 13, 2018 , ... Donaldson ... growing companies, as well as Columbus Business First's Fast 50 list of central Ohio's ... list with a 3-year growth rate of 81 percent. It is the only medical ...
(Date:9/7/2018)... , ... September 07, 2018 , ... ... and personal-care products with a presence worldwide, today announced that its Chief Executive ... Award in Entrepreneurship. Ms. Ishaq will be presented the award on Friday, September ...
(Date:9/7/2018)... ... September 07, 2018 , ... ... , the only OSHA authorized OTI Education Center headquartered in Northern California, is ... who feel they have experienced retaliation in response to engaging in activity protected ...
Breaking Medicine News(10 mins):
(Date:8/31/2018)... ... 31, 2018 , ... The summertime sweat that many people dread is a ... known as hyperhidrosis. In Grand Rapids , Dr. Brad Bengtson recognized the need ... frequently soak through their shirts for no reason other than the fact that their ...
(Date:8/31/2018)... , ... August 31, 2018 , ... Travel tech specialist ... with the insurance industry to create a new service for the disabled. The move ... specialist travel insurance. With 13,000,000 people in the UK living with a disability, Aquarium ...
(Date:8/31/2018)... ... August 31, 2018 , ... San Francisco Dental Implant Center, the Bay ... city," of Oakland, California, specifically targeted at those who live across the Bay and ... term ‘Bay Area’ encompasses a wide area and can include many nearby cities and ...
Breaking Medicine Technology:
Cached News: